407 ‒ Preventing cardiovascular and Alzheimer’s disease: lowering LDL early, APOE4, and more

Episode Overview

• Central Question & Scope: Cardiologist and lipidologist Dr. Michael Davidson (Professor and Director of the Lipid Clinic at the University of Chicago, seeing patients four full days a month, and CEO of NewAmsterdam Pharma) joins Dr. Peter Attia to examine whether a next-generation oral CETP inhibitor (obicetrapib) can simultaneously prevent atherosclerotic cardiovascular disease (ASCVD) by lowering LDL-C, Lp(a), and small dense LDL particles, and prevent Alzheimer’s disease by modifying brain lipid metabolism and biomarkers like p-tau217 in high-risk APOE $\varepsilon4$ carriers.
• Primordial Prevention & The History of CETP Inhibition: The discussion traces the shift from treating 10-year cardiovascular risk to eliminating lifetime cumulative LDL exposure ("the 8-gram rule"), followed by a forensic review of why four previous cholesteryl ester transfer protein (CETP) inhibitors failed or were shelved due to off-target adrenal toxicity, lack of LDL lowering, premature trial termination, or adipose tissue accumulation.
• Obicetrapib’s Clinical Profile & The Alzheimer’s Connection: Davidson details Phase 2 and Phase 3 data (TULIP, ROSE, ROSE2, BROOKLYN, BROADWAY, TANDEM) showing how a 10 mg daily dose of obicetrapib complements statins—lowering LDL-C by 35–50%, Lp(a) by ~50%, and small LDL particles by 90% while reducing diabetes risk—and reveals new BROADWAY sub-study data showing an over 20% reduction in plasma p-tau217 in APOE $\varepsilon4/\varepsilon4$ homozygotes.
• Omega-3 Transport, Statin Diabetes & Klotho: The episode concludes by contrasting EPA and DHA in cardiovascular and neurological health (highlighting the blood-brain barrier's MFSD2A transporter requirement for lyso-PC DHA), explaining why bile acid sequestrants and CETP inhibitors avoid statin-induced insulin resistance, and previewing human trials for the longevity protein klotho.
• Disclosures & Business Ties: Davidson discloses that he is CEO of NewAmsterdam Pharma (founded in early 2021 with John Kastelein; raised $200M in Series A and went public at the end of 2022), holds the first patent on CETP inhibition (issued in 1993), founded a clinical research company out of fellowship, previously founded/developed an IL-6 antibody at Corvidia Therapeutics (now in the ZEUS trial), helped develop the omega-3 drug Epanova (STRENGTH trial), and is involved with Jocasta. Attia and Davidson both disclose their direct involvement/investment in Jocasta (developing klotho protein and testing lyso-PC DHA).

Key Concepts

• Primordial Prevention & The "8-Gram Rule" of Cumulative LDL Exposure: Lowering LDL before a heart attack is highly effective, and lowering it after a heart attack still provides benefit, but clinical trials show no benefit to lowering LDL with statins once a patient develops heart failure. Davidson frames lifetime ASCVD risk through the "8-gram rule," where 8 grams of cumulative LDL-C exposure leads to heart disease: $200\text{ mg/dL} \times 40\text{ years} = 8\text{ grams}$ (heart disease at age 40); $100\text{ mg/dL} \times 80\text{ years} = 8\text{ grams}$ (age 80); $80\text{ mg/dL} \times 100\text{ years} = 8\text{ grams}$ (age 100). Keeping LDL-C below 80 mg/dL lifelong prevents heart disease. This is illustrated by Davidson’s personal history: after his father died of a heart attack at age 47 (when Davidson was 16 and his brother was 14; Attia notes his wife's grandfather also died at 47 in his 16-year-old son's hands), both brothers inherited severe familial lipid disorders. Davidson took niacin in medical school and statins immediately upon availability, remaining free of disease, whereas his brother (a family doctor) became a strict vegetarian, delayed statin therapy, and required coronary bypass surgery at age 44.
• Causal Drivers vs. 10-Year Risk Calculators: Crediting Allan Sniderman’s work (~12 years ago), Attia explains why treating 5-, 10-, or 15-year risk is flawed compared to treating causal drivers of disease. Just as a patient who has smoked 1 pack of cigarettes per day for 1 year (1 pack-year) does not yet have a meaningfully elevated cancer risk (which takes 15–20 pack-years) but would never be told by a doctor to keep smoking for another decade before quitting, clinicians should not wait for age-driven 10-year risk scores to rise before lowering elevated apoB/LDL-C.
• CETP Biology & Mammalian Resistance to Atherosclerosis: Cholesteryl ester transfer protein (CETP) transfers cholesterol from HDL into LDL; blocking it raises HDL, lowers LDL, increases hepatic LDL clearance, and routes more cholesterol into the intestines via bile (the majority of liver bile originates from HDL). Rats, mice, and dogs naturally lack the CETP gene, resulting in very high HDL, very low LDL, and natural immunity to atherosclerosis unless transgenically given the human CETP gene (a standard atherosclerotic animal model). Conversely, humans, monkeys, and rabbits possess CETP, giving them higher LDL and lower HDL.
• Why HDL Raising Alone Fails (Niacin & Mendelian Randomization): Before statins, the Coronary Drug Project showed niacin monotherapy raised HDL by 20–30% and modestly lowered cardiovascular events. However, on top of statins, the AIM-HIGH and HPS2-THRIVE trials failed to show cardiovascular benefit (though an HPS2-THRIVE reanalysis suggested a slight benefit matching its modest LDL lowering). Furthermore, a ~2012 Nature paper and Mendelian randomization studies proved that genetic variants that purely raise HDL-C do not protect against heart disease—and some high-HDL variants like SR-B1 (scavenger receptor class B type 1, enriched in Ashkenazi Jewish populations) and endothelial lipase variants, as well as alcohol consumption, raise HDL-C (e.g., to 100–110 mg/dL) while increasing cardiovascular risk or mortality. By contrast, genetic CETP loss-of-function reduces cardiovascular events specifically through its LDL/apoB lowering.
• Forensic Review of the 4 Previous CETP Inhibitors:
• Torcetrapib (Pfizer): Halted in December 2006. Studied with atorvastatin, it raised HDL-C by ~75% and lowered LDL-C by 10–15%, but increased cardiovascular and non-cardiovascular mortality and raised blood pressure by 3 to 5 mmHg. The failure was an off-target chemical effect: the molecule entered the adrenal glands and stimulated massive aldosterone and steroid production (proven off-target because giving torcetrapib to CETP-deficient rats spiked their blood pressure within 1 hour).
• Dalcetrapib (Roche): A weak CETP "modulator" that raised HDL-C by 30–40% with 0% LDL-C lowering. Across two large secondary prevention trials, it was safe and lowered diabetes risk, but was completely neutral on major adverse cardiac events (MACE).
• Evacetrapib (Eli Lilly — ACCELERATE trial): Raised HDL-C by ~75% and lowered LDL-C by 15–20% in high-risk acute coronary syndrome (ACS) patients. Stopped at 2 years for futility on primary MACE, though it lowered diabetes risk and achieved a statistically significant reduction in all-cause mortality (with near-significant CV mortality reduction). Davidson notes 2 years was too short, as both IMPROVE-IT (ezetimibe) and ODYSSEY Outcomes (alirocumab in patients with baseline LDL < 100 mg/dL) showed that LDL-lowering event curves do not separate until after 2 years.
• Anacetrapib (Merck — REVEAL trial): Studied in 30,000 patients over 4 years with a baseline LDL-C of 60 mg/dL. It lowered LDL-C by 17% relatively (11 mg/dL absolutely, down to 49 mg/dL) and reduced MACE by 9%, landing squarely on the Cholesterol Treatment Trialists' (CTT) regression line (where every 1 mmol/L or 38.8 mg/dL LDL-C drop yields a 22% relative risk reduction, with at best half that benefit in year one). Merck abandoned it because the highly lipophilic drug continuously accumulated in adipose tissue (confirmed by fat biopsies conducted by Davidson) and took years to wash out, posing pharmacokinetic and environmental/water-supply liabilities.
• Obicetrapib’s Pharmacology & Clinical Trial Data: Originally discovered by Mitsubishi Tanabe Pharma in Japan to be potent at a low dose (10 mg oral daily vs. 100+ mg for older CETP inhibitors) without fat accumulation, licensed to Amgen in 2017 (who improved manufacturing before shelving it after Repatha's slow launch), and acquired by NewAmsterdam in 2020/2021.
• Phase 2 (TULIP, ROSE, ROSE2): Showed 45–50% LDL-C lowering as monotherapy/add-on, ~55–60%+ LDL-C lowering combined with ezetimibe, and 150% HDL-C raising. In ROSE2, small dense LDL particles (via NMR) dropped by 90%, whereas apoB dropped more modestly (~16% noted by Attia, though non-HDL-C and LDL-P fell much more). Davidson explains this discordance occurs because apoB is a mass assay, and particle surface glycosylation (attached sugar molecules) slightly alters apoB mass measurement across different particle sizes.
• Phase 3 (BROOKLYN, BROADWAY, TANDEM & PREVAIL): BROOKLYN (1-year trial in heterozygous familial hypercholesterolemia [HeFH] on maximal therapy with baseline LDL-C ~100 mg/dL) showed 40% LDL-C lowering vs. placebo (to ~60 mg/dL). BROADWAY (52-week trial in 2,500 ASCVD patients, ~70% on high-intensity statins) showed ~35% LDL-C lowering and a 21% MACE reduction at 1 year (statistically significant in a landmark analysis excluding the first 6 months). TANDEM showed ~50% LDL-C lowering with a fixed-dose obicetrapib + ezetimibe pill. The ongoing PREVAIL cardiovascular outcomes trial (9,500 ASCVD patients across 400+ global sites with a minimum 2.5-year follow-up ending at the end of this year) is required to definitively prove MACE reduction. While filed in Europe (where the EMA approves on LDL lowering), US FDA filing is timed with PREVAIL to ensure payer reimbursement.
• Complementary Profile to Statins, Lp(a) Reduction & Pricing Dynamics: Statins slightly increase type 2 diabetes risk, increase Lp(a), poorly lower small LDL particles, and at maximal doses (e.g., 80 mg atorvastatin, 40 mg rosuvastatin, or combined with ezetimibe) frequently elevate liver transaminases (AST/ALT to ~80 U/L)—though placebo-controlled trials show true statin intolerance is only ~4.9%. Obicetrapib lowers diabetes risk, wipes out small LDL particles by 90%, and lowers Lp(a) by ~50% in the moderate-to-high band (50–150 nmol/L or mg/dL) by reducing Lp(a) synthesis (though Davidson hedges that the exact mechanism of Lp(a) lowering by CETP and PCSK9 inhibitors is not fully understood). Contextually, the Phase 3 Lp(a) HORIZON trial (pelacarsen) had to be extended due to low event rates because patients' baseline LDL-C was reduced to 60 mg/dL, demonstrating that aggressive LDL lowering mitigates Lp(a) risk. On pricing, Attia notes Repatha's $16,000/year launch blunder and Nexletol's ~$6,000/year price; Davidson explains that US Pharmacy Benefit Managers (PBMs) refuse to place low-priced drugs (like branded Zetia) on formulary because they cannot extract large rebate profits, forcing drugmakers to inflate list prices unless direct-to-consumer models (like LillyDirect) bypass PBMs.
• Brain Lipid Homeostasis, APOE $\varepsilon4$ & CETP in Alzheimer’s Disease:
• Isolated Brain Lipids: The brain makes up 2% of body weight but holds 50% of total body cholesterol (myelin is 50% cholesterol). Neurons synthesize cholesterol in childhood, then rely on astrocytes in adulthood for cholesterol synthesis, transport, and waste clearance. Because the blood-brain barrier (BBB) isolates the brain, there is zero apoB and zero LDL in the brain—only apoE and HDL-like particles. Receiving an APOE $\varepsilon3$ liver transplant changes blood apoE to $\varepsilon3$, but the brain remains APOE $\varepsilon4$ (and whether liver-directed gene therapy could help the brain remains unknown).
• Pathophysiology of APOE $\varepsilon4$: While most people are $\varepsilon3/\varepsilon3$ and $\varepsilon2$ is protective, 20–25% carry one $\varepsilon4$ allele ($\varepsilon3/\varepsilon4$, ~3x AD risk, onset ~10 years earlier) and 2–3% are $\varepsilon4/\varepsilon4$ homozygotes (~10x risk, onset ~20 years earlier). APOE $\varepsilon4$ astrocytes have impaired cholesterol efflux; excess un-cleared cholesterol converts into toxic oxysterols (24S-hydroxycholesterol and 27-hydroxycholesterol) that cross the BBB and trigger neuroinflammation, amyloid plaques, and tau tangles. Small HDL particles (via peripheral apoA1—which Davidson notes is likely not synthesized in the brain—and SR-B1 receptors in the choroid plexus/BBB) clear excess brain cholesterol/amyloid and deliver antioxidants.
• Genetic, Animal & Human Biomarker Evidence: In the Bronx Aging Study of 400 Ashkenazi Jews aged ~100+, CETP loss-of-function was the top healthy-aging gene, and inheriting it alongside APOE $\varepsilon4$ completely abolishes the excess $\varepsilon4$ Alzheimer's risk. At McGill University, adding the human CETP gene to APP Alzheimer's mice markedly worsened amyloid and dementia, while a CETP inhibitor rescued their cognition/nesting behavior. In an Amsterdam pilot study of 13 APOE $\varepsilon4$ MCI patients (funded with $1M from NewAmsterdam's Series A), obicetrapib lowered CSF 24S- and 27-hydroxycholesterol (which statins do not do) and raised CSF antioxidants. In a pre-specified 12-month sub-study of the BROADWAY trial ($N=2,500$, mean age 65), obicetrapib significantly blunted the rise of plasma p-tau217* overall, with the most profound effect in APOE $\varepsilon4/\varepsilon4$ homozygotes ($n=30$), who showed an over 20% reduction in p-tau217 vs. placebo, plus improvements across p-tau181, A$\beta$ 42/40 ratio, GFAP, and NfL*.
• Caveats & Next Steps: Both speakers heavily caveat that the homozygote subgroup had only 30 patients, and it remains unknown if lowering p-tau217 with a lipid drug will reverse or halt clinical dementia (Attia invokes Richard Feynman's warning: "the easiest person to fool is yourself"). Unlike GLP-1 trials (EVOKE / EVOKE Plus), which failed to improve cognition or p-tau217, and anti-amyloid antibodies (like donanemab in TRAILBLAZER, which correlate p-tau217 reduction with cognitive benefit but carry brain bleeding/ARIA risks in $\varepsilon4$ homozygotes), obicetrapib is safe in $\varepsilon4/\varepsilon4$ carriers. NewAmsterdam is launching a prospective trial in 300 pre-Alzheimer's patients (aged 60+, elevated tau/biomarkers, APOE $\varepsilon4$, pre-MCI) to validate these findings.
• Omega-3s (EPA vs. DHA) & The MFSD2A Blood-Brain Barrier Transporter:
• Cardiovascular (EPA): Comparing STRENGTH (4 g/day Epanova [EPA+DHA] vs. corn oil; neutral overall), REDUCE-IT (4 g/day pure EPA vs. mineral oil; 25% MACE reduction, though mineral oil raised LDL-C by 9–10% and increased inflammation), and PROMINENT (pemafibrate; neutral on MACE) proves that lowering triglycerides does not reduce CV events; rather, pure EPA reduces events via anti-thrombotic and anti-inflammatory effects on the arachidonic acid pathway.
• Neurological (DHA): Although DHA is the brain's primary fatty acid and APOE $\varepsilon4$ carriers have impaired brain DHA uptake (shown by Hussein Yassine), standard DHA supplements fail in cognitive trials because the BBB's MFSD2A transporter only accepts DHA in the lyso-phosphatidylcholine (lyso-PC DHA) form. Raising red blood cell Omega-3 Index from 4% to 10% with standard fish oil helps the heart (via EPA) but does not effectively deliver DHA to the brain.
• AI in Clinical Trials, Statin-Induced Diabetes & Klotho:
• Per-Protocol AI Modeling: With drug development costing $1 billion to $3–4 billion (including failures), Davidson advocates using AI modeling to evaluate on-treatment / per-protocol efficacy (>80% compliance) rather than diluting trials with non-compliant dropouts in intention-to-treat analyses, potentially shrinking trials from 10,000 to 2,000 patients.
• Statin Diabetes vs. Bile Acid Sequestrants: While the exact mechanism of statin-induced diabetes remains an enigma (risk increases with dose, age, and obesity, and is shared by PCSK9i and NPC1L1 inhibition), CETP inhibitors and bile acid sequestrants (which lower LDL-C by 10–15%) improve glycemic control because synthesizing replacement bile acids in the liver consumes substantial glucose.
• Klotho Protein (Jocasta): Genetic klotho variants protect APOE $\varepsilon4$ carriers from AD, and peripheral klotho injections boost cognition in mice and non-human primates (work by Dena Dubal in Nature Aging). After WuXi Biologics solved large-scale manufacturing, Jocasta is preparing an IND for human trials in ~1 year (though klotho's exact mechanism and whether a cleaved fragment crosses the BBB remain unknown).

Quotes

• At 3:31 - "You want to stop plaque from forming before it's there. It's a lot easier to stop it from forming than it is to reversing it when it already exists." - Davidson explaining the foundational principle of primordial cardiovascular prevention.
• At 4:04 - "If you lower LDL before you have a heart attack, it's very effective. If you have a heart attack and you lower LDL, it still has benefit. But once you have heart failure, there's no benefit to lowering LDL." - Davidson highlighting why timing is critical in lipid-lowering therapy and why late-stage intervention fails.
• At 4:21 - "What I like is the 8-gram rule, which is that 8 grams of cholesterol in your lifetime lead to heart disease. So that is 200 milligrams per deciliter times 40 years is 8 grams, or 100 milligrams per deciliter times 80 years is 8 grams, or 80 milligrams per deciliter times 100 years is 8 grams." - Davidson providing a mathematical framework for cumulative lifetime LDL-C exposure.
• At 4:44 - "The data says that if you keep your LDL below 80 throughout your lifetime, you don't get heart disease." - Davidson defining the target threshold for lifelong primordial prevention of ASCVD.
• At 8:48 - "It is that smoking is causally related to cancer, and therefore the time to quit smoking is before you start, and if you've already started, the time to quit smoking is today, regardless of your risk going forward." - Attia using the pack-year smoking analogy to explain why clinicians should treat causal risk factors (like apoB) early rather than waiting for 10-year risk scores to rise.
• At 16:14 - "It's called cholesteryl ester transfer protein. It transfers cholesterol, you know, from HDL into LDL. So when you block it, HDL goes up, LDL goes down." - Davidson explaining the core physiological mechanism of CETP inhibition.
• At 22:24 - "Well, the blood pressure increase actually was the, was only the tip of the iceberg. The drug had a very prominent effect on increasing, getting to the adrenal glands, and would markedly increase aldosterone and steroid production." - Davidson detailing why the first CETP inhibitor, torcetrapib, caused off-target mortality in patients.
• At 35:08 - "They got a 17% LDL lowering, 11 milligrams per deciliter absolute LDL lowering, and they got a 9% relative risk reduction, which is what you'd expect, if not more so what you'd expect. And so it proved the LDL lowering benefit with CETP inhibition can translate into a cardiovascular benefit." - Davidson discussing how Merck's REVEAL trial of anacetrapib validated the CETP mechanism for MACE reduction.
• At 38:20 - "For a 1 millimole, which is 38.8 milligrams per deciliter of LDL, you get a 22% relative risk reduction." - Davidson stating the Cholesterol Treatment Trialists' (CTT) Collaboration linear formula linking absolute LDL-C reduction to cardiovascular event reduction.
• At 40:10 - "There's nothing special about statins other than they're, you know, very effective and well tolerated, but there's nothing special about the LDL lowering about statins that result in a greater benefit than any other LDL lowering drug that can achieve the same levels in a patient." - Davidson clarifying that cardiovascular protection depends on the magnitude and duration of LDL lowering rather than statin-specific pleiotropic effects.
• At 59:10 - "Small particles go down by 90%, you know, you wipe out small particles, but apoB doesn't go down as much as you'd expect." - Davidson describing the ROSE2 trial findings and the assay discordance between NMR small LDL particle reductions and apoB mass measurements.
• At 1:05:30 - "What do statins not do so well? It raises the risk of diabetes slightly, it raises the Lp(a), and it does not lower small particles very well, it lowers mostly the non-small particles. What does obicetrapib do well? It lowers the risk of diabetes based on our BROADWAY trial data, as well as other CETP inhibitors, it lowers Lp(a) in that 50% range in that moderate band, and it lowers the small particles by 90%." - Davidson explaining how obicetrapib directly offsets the metabolic and lipid liabilities of statin therapy.
• At 1:08:05 - "You're getting virtually all the bang for your buck at that lowest dose, and that curve is so concave down that it's almost unjustifiable to be on a statin above 50% of its max dose." - Attia advocating for low-to-moderate dose statins paired with add-on therapies to avoid high-dose statin toxicity and elevated liver transaminases.
• At 1:10:27 - "If you price too low, the PBMs don't have any rebating profits to make, so they don't put it on formulary. And so you gotta be able to play the rebate game and price it accordingly." - Davidson revealing how Pharmacy Benefit Manager (PBM) incentives distort US drug pricing and formulary access.
• At 1:13:20 - "Then later came the data showing that if you have APOE4 and you have the CETP loss of function, your risk of Alzheimer's is significantly mitigated." - Davidson citing human genetic longevity data linking CETP loss-of-function to protection against APOE $\varepsilon4$-driven Alzheimer's disease.
• At 1:19:52 - "The blood-brain barrier completely separates off the brain lipid metabolism from the rest of the body. There's no apoB in the brain, there's no apoB. It's all apoE and HDL in the brain." - Davidson explaining why peripheral LDL/apoB metabolism is entirely separate from central nervous system cholesterol transport.
• At 1:31:41 - "Alzheimer's is not a disease of old age. It's a disease of middle age that presents in old age." - Attia emphasizing that neurodegenerative pathology begins decades before cognitive symptoms appear, requiring midlife intervention.
• At 1:41:01 - "If they were 4/4, homozygotes, we saw this profound benefit on not just p-tau217, over 20% difference from placebo, but all the biomarkers improved: 181, amyloid 42/40, GFAP, neurofilament light, all got better with obicetrapib." - Davidson sharing the 12-month BROADWAY sub-study results in the 30 APOE $\varepsilon4/\varepsilon4$ homozygote patients.
• At 1:54:19 - "What that says is that EPA does work on reducing events, not for triglyceride lowering, it's more for the anti-thrombotic, anti-inflammatory effect." - Davidson synthesizing the lessons from the STRENGTH, REDUCE-IT, and PROMINENT trials regarding omega-3 fatty acids and triglycerides.
• At 1:55:02 - "A new discovery which is very exciting is the MFSD2A transporter... It's a transporter across the blood-brain barrier for DHA. It turns out that DHA prefers the lyso-PC form, a lysophosphatidylcholine form of DHA, that's the preferred substrate for DHA to cross the blood-brain barrier." - Davidson explaining why standard over-the-counter DHA supplements fail to effectively enter the brain.

Takeaways

• Target Lifetime LDL-C Below 80 mg/dL Early in Adulthood: Use the "8-gram rule" ($80\text{ mg/dL} \times 100\text{ years} = 8\text{ grams}$) as a guide for primordial prevention; do not wait for 10-year cardiovascular risk scores to become elevated in middle or old age before initiating lipid-lowering therapy if apoB/LDL-C is high.
• Do Not Rely on Diet Alone for Familial Hypercholesterolemia: If you have a strong family history or genetic predisposition to high LDL-C, recognize that strict dietary interventions (such as vegetarianism) are often insufficient on their own to prevent premature coronary artery disease and should be paired with early pharmacological intervention.
• Avoid Maximal-Dose Statin Monotherapy in Favor of Combination Therapy: Because statin efficacy curves flatten out while side effects (such as elevated liver transaminases AST/ALT and insulin resistance) spike at maximum doses (e.g., 80 mg atorvastatin or 40 mg rosuvastatin), use a low-to-moderate dose statin (at or below 50% of the max dose) and layer on complementary non-statin agents (such as ezetimibe, PCSK9 inhibitors, or upcoming CETP inhibitors).
• Do Not Treat High HDL-C as Cardioprotective: Never use a high HDL-C level (e.g., 90–110 mg/dL) as an excuse to ignore elevated LDL-C or apoB, as high HDL-C can be driven by dysfunctional genetic variants (like SR-B1 or endothelial lipase) or alcohol intake that actually increase cardiovascular risk.
• Aggressively Lower LDL-C to Mitigate Elevated Lp(a) Risk: While awaiting dedicated Lp(a)-lowering outcome readouts (like Lp(a) HORIZON) or oral options like obicetrapib (which lowers moderate-band Lp(a) by ~50%), drive LDL-C down to ~60 mg/dL or lower, which substantially blunts the excess event rate caused by high Lp(a).
• Monitor Glycemic Markers When Starting Statins in Pre-Diabetic Patients: In older, overweight, or insulin-resistant patients where statin-induced diabetes is a concern, keep statin doses low and consider adjunctive therapies that improve or do not worsen glucose metabolism, such as bile acid sequestrants (which lower LDL-C by 10–15% and lower glucose) or CETP inhibitors once approved.
• Test Your APOE Genotype in Early or Mid-Adulthood: Because Alzheimer's pathology begins in middle age—10 to 20 years earlier in APOE $\varepsilon3/\varepsilon4$ heterozygotes and $\varepsilon4/\varepsilon4$ homozygotes—determine your APOE status decades before symptoms arise so you can implement aggressive midlife prevention before Mild Cognitive Impairment (MCI) sets in.
• Prioritize Midlife Vascular, Metabolic, and Exercise Interventions for APOE $\varepsilon4$ Carriers: Since statins do not lower brain oxysterols (24S- and 27-hydroxycholesterol) and anti-amyloid antibodies carry high ARIA/bleeding risks in $\varepsilon4/\varepsilon4$ homozygotes, APOE $\varepsilon4$ carriers should aggressively manage blood pressure, metabolic health, and cardiorespiratory fitness in their 40s and 50s while monitoring emerging preventative trials (such as obicetrapib's upcoming pre-Alzheimer's trial).
• Use Plasma p-tau217 to Track Early Alzheimer's Pathology (With Appropriate Caution): For high-risk individuals evaluating early neurodegenerative changes in clinical or research settings, plasma p-tau217 is currently the most sensitive blood biomarker for tracking amyloid and tau pathology, though patients and clinicians must remember it is not yet a proven clinical surrogate for cognitive reversal.
• Use High-Dose Pure EPA (Not Fibrates or Standard Mixed Fish Oil) for Cardiovascular Risk Reduction: When targeting residual cardiovascular risk beyond apoB/LDL lowering, rely on EPA for its anti-thrombotic and anti-inflammatory properties rather than attempting to lower triglycerides with fibrates (like pemafibrate), which do not reduce cardiovascular events.
• Do Not Rely on Standard Over-the-Counter DHA Supplements to Prevent Alzheimer's: Understand that while standard EPA/DHA fish oil raises red blood cell Omega-3 Index (e.g., from 4% to 10%) and benefits the heart, free/triglyceride DHA does not efficiently cross the blood-brain barrier; brain delivery requires DHA bound to lysophosphatidylcholine (lyso-PC DHA) to utilize the MFSD2A transporter.
• Evaluate Cardiovascular Lipid Trials Over Multi-Year Horizons: When interpreting clinical trial readouts for lipid-lowering therapies, recognize that plaque stabilization and regression take time—only half of the expected risk reduction occurs in year one, and event curves often take more than 2 years to separate—meaning short trials (<2 years) can falsely appear futile.